30 Dec 2013 10:53
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- Stock Screeners
- Share Chat
- FX
- News & RNS
- Events
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Imperial Innovations Group Share News (IVO)
IVO Share
Price
IVO Share
News
IVO Share
Chat
IVO Share
Trades
IVO
Live RNS
IVO Share
Charts
IVO Broker
Ratings
IVO Directors
Deals
IVO Financial
Diary
IVO
Fundamentals
IVO Short
Positions
IVO
Media
Imperial Innovations Group Information
- There is currently no data for IVO
Watchlists are a member only feature
Login to your account
Don't have an account? Click here to register.Imperial Innovations shares up on portfolio company progress
Thu, 06th Oct 2016 15:15
(ShareCast News) - Imperial Innovations Group updated the market on Thursday, noting that its portfolio company TopiVert Pharma has announced that the first patients have been dosed in its Phase IIa proof-of-concept study to evaluate the safety, tolerability and efficacy of a rectal formulation of TOP1288 in symptomatic ulcerative colitis patients with moderate to severe disease activity.The AIM-traded firm said TOP1288, a potent inhibitor of key kinases involved in inflammation, is being developed by TopiVert as a topical therapy for the form of inflammatory bowel disease which affects the colon.On 17 March, TopiVert reported the successful completion of a Phase I study in healthy volunteers.The clinical data supported the concept that TOP1288 has the potential to produce sustained pharmacological effects in mucosal tissues after local administration, but without the undesirable side effects often seen in UC patients treated with systemically available therapies.Imperial explained that the new Phase II study will evaluate the efficacy, safety and tolerability of TOP1288 administered once daily for four weeks in symptomatic UC patients with moderate to severe disease activity.The study will recruit up to 60 patients at sites across eight European countries and is anticipated to report in the second half of 2017.TopiVert will also commence a follow-on Phase I study with the oral formulation of TOP1288 in early 2017, with that study also expected to report in the second half of 2017."We are delighted by the progress that TopiVert is making, both in its ulcerative colitis trials, but also with its second programme, TOP1630, in dry eye disease, for which a first-in-human proof-of-concept study is planned for early 2017," said Imperial director of healthcare ventures Maina Bhaman.At 1111 BST, shares in Imperial Innovations were up 3% at 435.93p.
More News
17 Oct 2013 07:07
Thursday tips round-up: Imperial Innovations, Vertu Motors
Imperial Innovations has the right to take interesting discoveries from Imperial College London and package them up into companies that eventually can be floated or sold. The majority of its 92 investments are in pharmaceuticals; one of the most promising, Circassia, is well into clinical trials for
Read more16 Oct 2013 11:25
Imperial Innovations portfolio value rises as companies near IPO
Imperial Innovations accompanied news of a full year rise in its portfolio value with the announcement of a Nasdaq flotation for portfolio company Oxford Immunotec. The university spin-out group said had "a number" of companies in its portfolio also ready for initial public offering (IPO) or trade
Read more16 Oct 2013 10:36
17 Jul 2013 10:39
Innovations CEO steps down
Technology commercialisation and investment group Imperial Innovations confirmed that Chief Executive Susan Searle has stepped down after 11 years in the role. Chief investment officer Russ Cummings, who has been a director since the group's flotation in 2006, has taken over as CEO with immediate
Read more29 Apr 2013 12:15
Kelsey Lynn appointed Director of Technology Ventures at Imperial Innovations Group
AIM-listed technology commercialisation and investment group Imperial Innovations Group has reported that that Kelsey Lynn has joined as Director of Technology Ventures with immediate effect. Lynn spent the last twelve years in California, working in new technology development and venture capital
Read more22 Mar 2013 08:44
Imperial Innovations reports strong progress in top three portfolio companies
Imperial Innovations, a technology commercialisation and investment group, on Friday reported 'really good' progress in its top three portfolio companies in its half year results. The firm said that in the six months ended January 31st its top three portfolio companies, namely Circassia, Nexeon an
Read more22 Feb 2013 11:40
Imperial Innovations reports that Nexeon signed partnership with WACKER
AIM-listed technology commercialisation and investment group Imperial Innovations has announced that portfolio company Nexeon, a battery materials and licensing company, has signed a strategic partnership agreement with German chemical company WACKER Chemie AG (WACKER). The group reported that WAC
Read more23 Jan 2013 08:21
Imperial Innovations invests 1.5m pounds in tech firm Semetric
Technology commercialisation and investment group Imperial Innovations has invested 1.5m pounds in technology firm Semetric, the company behind global music analytics specialist, Musicmetric. The group said that the investment was part of a £3m funding round which also included its existing investo
Read more5 Oct 2012 13:18
Imperial Innovations rises to university challenge
A change in the fair value of investments held by Imperial Innovations, the hot-house for technology and healthcare ideas from Britain's universities, saw full year profits surge. Revenues eased, however, reflecting the continuing difficult economic environment. Total revenues in the year to the en
Read more